Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III comparison of HLX02 versus EU-sourced Herceptin in previously untreated HER2-positive metastatic breast cancer
2016-000206-10Phase 3Completed
- Sponsor
- Henlius
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of trastuzumab in breast cancer (2 arms), sponsored by Henlius. Primary endpoint: Overall response rate through Week 24. Started Apr 2017; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-000206-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000206-10.